Journal
CURRENT DIABETES REPORTS
Volume 8, Issue 2, Pages 87-93Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-008-0017-y
Keywords
-
Categories
Funding
- Juvenile Diabetes Research Foundation [8-2006-1091, 11-2005-1117, 11-2005-15]
- German Federal Ministry for Research and Education [01KG0704]
Ask authors/readers for more resources
Mucosal administration of insulin represents an attractive antigen-specific therapeutic approach to preventing type 1 diabetes. It can prevent autoimmune diabetes in animal models, but although it has been shown to be safe, it has not yet been proven effective in human studies. Efficacy may depend on the dose and route at which insulin is administered, the stage in type 1 diabetes pathogenesis at which treatment is initiated, and the study cohort that is treated. We have proposed Pre-POINT (Primary Oral/intranasal INsulin Trial), a dose-finding safety and immune efficacy pilot study for primary mucosal insulin therapy in islet autoantibody-negative children at high genetic risk for type 1 diabetes who naturally first develop autoimmunity to insulin. Pre-POINT aims to identify an optimal insulin dose and route of application (orally or intranasally) that is well tolerated and can induce an immune response to insulin for additional use in a phase II/III primary prevention trial in children at risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available